Covered recipient · General Payments record
JASWINDER SINGH
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$5,473.31
157 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,380.37 | 154 |
| Consulting Fee | $1,953.00 | 1 |
| Education | $139.94 | 2 |
By paying entity
PY2023 · entire year · sorted by reported total
Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JASWINDER SINGH
NPI 1093747677 · CMS profile ID 185961
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
KANSAS CITY, MO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1093747677?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JASWINDER SINGH, NPI 1093747677, CMS profile ID 185961. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093747677?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). JASWINDER SINGH, NPI 1093747677, CMS profile ID 185961. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093747677?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- JASWINDER SINGH, NPI 1093747677, CMS profile ID 185961, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1093747677?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
157 matching records · $5,473.31 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 157.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Celgene Corporation | $15.13 | 08/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015662529 | CMS |
| Seagen Inc. | $14.40 | 08/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995728045 | CMS |
| E.R. Squibb & Sons, L.L.C. | $12.80 | 08/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015662515 | CMS |
| Gilead Sciences, Inc. | $17.15 | 08/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025923955 | CMS |
| Genentech USA, Inc. | $4.64 | 08/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040390891 | CMS |
| Genentech USA, Inc. | $11.39 | 08/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040390907 | CMS |
| Genentech USA, Inc. | $0.91 | 08/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040390897 | CMS |
| Seagen Inc. | $7.20 | 08/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995728113 | CMS |
| Blueprint Medicines Corporation | $18.23 | 08/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051255627 | CMS |
| GlaxoSmithKline, LLC. | $108.14 | 08/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001702051 | CMS |
| PFIZER INC. | $10.33 | 08/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050090649 | CMS |
| ARRAY BIOPHARMA INC | $21.29 | 08/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049901901 | CMS |
| Janssen Biotech, Inc. | $18.68 | 08/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988231845 | CMS |
| ARRAY BIOPHARMA INC | $1.66 | 08/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049925291 | CMS |
| Astellas Pharma US Inc | $29.55 | 08/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034371159 | CMS |
| Stemline Therapeutics Inc. | $15.50 | 08/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040028145 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.33 | 07/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015662507 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.98 | 07/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015774143 | CMS |
| AVEO Pharmaceuticals, Inc. | $23.06 | 07/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049060151 | CMS |
| Astellas Pharma US Inc | $12.77 | 07/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034327441 | CMS |
| TerSera Therapeutics LLC | $29.92 | 07/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1052417969 | CMS |
| Exelixis Inc. | $15.61 | 07/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044581005 | CMS |
| Janssen Biotech, Inc. | $22.39 | 07/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988231855 | CMS |
| Gilead Sciences, Inc. | $16.88 | 07/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025932789 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1.80 | 07/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015662471 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4.83 | 07/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015662475 | CMS |
| Celgene Corporation | $14.46 | 07/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015662511 | CMS |
| Mylan Inc. | $1,953.00 | 07/10/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1038964495 | CMS |
| GlaxoSmithKline, LLC. | $15.09 | 07/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001707855 | CMS |
| GlaxoSmithKline, LLC. | $0.28 | 07/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001701997 | CMS |
| ARRAY BIOPHARMA INC | $15.53 | 06/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049987175 | CMS |
| ARRAY BIOPHARMA INC | $3.67 | 06/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049945141 | CMS |
| GENZYME CORPORATION | $14.56 | 06/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050032959 | CMS |
| AbbVie Inc. | $34.56 | 06/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999026699 | CMS |
| E.R. Squibb & Sons, L.L.C. | $11.60 | 06/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015662465 | CMS |
| Foundation Medicine, Inc. | $72.71 | 06/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1058787415 | CMS |
| Exelixis Inc. | $18.85 | 06/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044568877 | CMS |
| AbbVie Inc. | $18.17 | 06/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999026695 | CMS |
| Genentech USA, Inc. | $18.85 | 06/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040390883 | CMS |
| Exelixis Inc. | $18.37 | 06/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044565791 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $24.14 | 06/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996564187 | CMS |
| Regeneron Healthcare Solutions, Inc. | $17.01 | 05/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999447841 | CMS |
| Seagen Inc. | $21.00 | 05/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995727935 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.72 | 05/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011944677 | CMS |
| Janssen Biotech, Inc. | $99.95 | 05/17/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988231877 | CMS |
| Janssen Biotech, Inc. | $18.59 | 05/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988231895 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $26.29 | 05/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998295757 | CMS |
| Kite Pharma, Inc. | $17.52 | 05/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025273833 | CMS |
| Genentech USA, Inc. | $15.98 | 05/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040390861 | CMS |
| Exelixis Inc. | $17.46 | 05/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044550165 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $737,050.48 | 66 |
| PY2024 | Principal investigator | $1,264,840.10 | 143 |
| PY2023 | Principal investigator | $563,788.52 | 115 |
| PY2022 | Principal investigator | $276,025.26 | 28 |
| PY2021 | Principal investigator | $876,361.06 | 59 |
| PY2020 | Principal investigator | $99,529.36 | 11 |
| PY2019 | Principal investigator | $53,849.18 | 20 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
66 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,780.95 | 12/31/2025 | Non-covered Recipient Entity Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411638 |
| Principal investigator 1 | PFIZER INC. | $4,212.92 | 12/31/2025 | Non-covered Recipient Entity American Oncology Partners PA | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228815499 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,209.00 | 12/29/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175415048 |
| Principal investigator 1 | PFIZER INC. | $24,273.44 | 12/29/2025 | Covered Recipient Teaching Hospital Amend #1 Research Medical Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228708716 |
| Principal investigator 1 | PFIZER INC. | $2,000.00 | 12/29/2025 | Covered Recipient Teaching Hospital Amend #1 Research Medical Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228708720 |
| Principal investigator 1 | PFIZER INC. | $28,297.52 | 12/29/2025 | Covered Recipient Teaching Hospital Amend #1 Research Medical Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228708926 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,312.00 | 12/25/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175415068 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $21,216.00 | 12/22/2025 | Non-covered Recipient Entity MidAmerica Cancer Care | A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1232935713 |
| Principal investigator 1 | PFIZER INC. | $2,750.00 | 12/19/2025 | Non-covered Recipient Entity MIDAMERICA CANCER CARE | A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA | No dispute reported | 06/30/2026 | 1228815134 |
| Principal investigator 1 | PFIZER INC. | $18.95 | 12/05/2025 | Non-covered Recipient Entity MIDAMERICA CANCER CARE | A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA | No dispute reported | 06/30/2026 | 1228815151 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,780.95 | 12/03/2025 | Non-covered Recipient Entity Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411738 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,999.80 | 12/01/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | Fruquintinib | No dispute reported | 06/30/2026 | 1223289114 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $50,884.30 | 11/13/2025 | Non-covered Recipient Entity MIDAMERICA CANCER CARE LLC | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185543404 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,768.00 | 11/03/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175414992 |
| Principal investigator 1 | PFIZER INC. | $1,703.70 | 10/24/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228825585 |
| Principal investigator 1 | PFIZER INC. | $3,855.92 | 10/22/2025 | Non-covered Recipient Entity American Oncology Partners PA | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228824964 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,780.95 | 10/15/2025 | Non-covered Recipient Entity Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410078 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,780.95 | 10/15/2025 | Non-covered Recipient Entity Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410086 |
| Principal investigator 1 | PFIZER INC. | $4,694.24 | 10/15/2025 | Non-covered Recipient Entity American Oncology Partners PA | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228825623 |
| Principal investigator 1 | Janssen Research & Development, LLC | $726.00 | 10/02/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175415061 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 09/29/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175415004 |
| Principal investigator 1 | Amgen Inc. | $23,927.34 | 09/23/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA DBA ONCOLOGY HEMATOLOGY ASSOCIATES | A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1246639101 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,511.00 | 09/08/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175415042 |
| Principal investigator 1 | Amgen Inc. | $5,075.00 | 08/23/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA DBA ONCOLOGY HEMATOLOGY ASSOCIATES | A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1246639099 |
| Principal investigator 1 | PFIZER INC. | $14,200.00 | 08/23/2025 | Non-covered Recipient Entity American Oncology Partners PA | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228830433 |
| Principal investigator 1 | Ares Trading SA | $800.00 | 08/01/2025 | Non-covered Recipient Entity American Oncology Partners PA | A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy | No dispute reported | 06/30/2026 | 1241194005 |
| Principal investigator 1 | Ares Trading SA | $1,900.00 | 08/01/2025 | Non-covered Recipient Entity American Oncology Partners PA | A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy | No dispute reported | 06/30/2026 | 1241194007 |
| Principal investigator 1 | Ares Trading SA | $2,500.00 | 08/01/2025 | Non-covered Recipient Entity American Oncology Partners PA | A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy | No dispute reported | 06/30/2026 | 1241194009 |
| Principal investigator 1 | Ares Trading SA | $1,100.00 | 08/01/2025 | Non-covered Recipient Entity American Oncology Partners PA | A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy | No dispute reported | 06/30/2026 | 1241194011 |
| Principal investigator 1 | AstraZeneca UK Limited | $135,102.30 | 08/01/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185543400 |
| Principal investigator 1 | AstraZeneca UK Limited | $173,082.65 | 07/30/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS P A | a phase III,open label,sponsor blind,randomized study of dato dxd with or without osimertinib versus platinum based doublet chemotherapy for participants with egfr mutated locally advanced or metastatic non small cell lung cancer whose disease has progressed on prior osimertinib treatment tropion lung15 | No dispute reported | 06/30/2026 | 1185543398 |
| Principal investigator 1 | PFIZER INC. | $2,257.20 | 07/28/2025 | Non-covered Recipient Entity MidAmerica Cancer CareAmerican Oncology Partners | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228713579 |
| Principal investigator 1 | Incyte Corporation | $1,121.20 | 07/25/2025 | Non-covered Recipient Entity MIDAMERICA CANCER CARE | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib | No dispute reported | 06/30/2026 | 1240557826 |
| Principal investigator 1 | PFIZER INC. | $3,855.92 | 07/25/2025 | Non-covered Recipient Entity American Oncology Partners PA | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228830195 |
| Principal investigator 1 | PFIZER INC. | $6,244.04 | 07/16/2025 | Non-covered Recipient Entity American Oncology Partners PA | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228830247 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $22,630.00 | 07/15/2025 | Non-covered Recipient Entity American Oncology Partners | A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | No dispute reported | 06/30/2026 | 1236531279 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,780.95 | 07/14/2025 | Non-covered Recipient Entity Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408708 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,780.95 | 07/14/2025 | Non-covered Recipient Entity Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408730 |
| Principal investigator 1 | Janssen Research & Development, LLC | $726.00 | 07/04/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175414984 |
| Principal investigator 1 | PFIZER INC. | $3,855.92 | 07/02/2025 | Non-covered Recipient Entity American Oncology Partners PA | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228830366 |
| Principal investigator 1 | PFIZER INC. | $838.32 | 06/26/2025 | Non-covered Recipient Entity American Oncology Partners PA | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228829431 |
| Principal investigator 1 | PFIZER INC. | $3,855.92 | 05/30/2025 | Non-covered Recipient Entity American Oncology Partners PA | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228829366 |
| Principal investigator 1 | PFIZER INC. | $838.32 | 05/14/2025 | Non-covered Recipient Entity American Oncology Partners PA | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228833488 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,072.00 | 05/02/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | Fruquintinib | No dispute reported | 06/30/2026 | 1223278892 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,550.00 | 04/28/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175414977 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,780.95 | 04/24/2025 | Non-covered Recipient Entity Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405616 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,780.95 | 04/24/2025 | Non-covered Recipient Entity Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406218 |
| Principal investigator 1 | PFIZER INC. | $3,855.92 | 04/23/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228832798 |
| Principal investigator 1 | PFIZER INC. | $838.32 | 04/16/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228831778 |
| Principal investigator 1 | PFIZER INC. | $3,855.92 | 04/09/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228833071 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,838.00 | 04/07/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175415036 |
| Principal investigator 1 | Incyte Corporation | $450.00 | 03/24/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240501857 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,464.00 | 03/20/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARC H LLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175400688 |
| Principal investigator 1 | PFIZER INC. | $838.32 | 03/12/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228832852 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $480.00 | 03/03/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226146008 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $201.74 | 02/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARC | A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S | No dispute reported | 06/30/2026 | 1192162458 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $10,011.40 | 02/13/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185543402 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,890.00 | 02/10/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARC H LLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175400747 |
| Principal investigator 1 | Amgen Inc. | $45,431.63 | 01/30/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1246639019 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,780.95 | 01/29/2025 | Non-covered Recipient Entity Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225403759 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,780.95 | 01/29/2025 | Non-covered Recipient Entity Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405732 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,833.05 | 01/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARC | A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S | No dispute reported | 06/30/2026 | 1192162454 |
| Principal investigator 1 | PFIZER INC. | $1,600.52 | 01/15/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228832618 |
| Principal investigator 1 | ABBVIE INC. | $3,206.00 | 01/09/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | M18-868 - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202437606 |
| Principal investigator 1 | PFIZER INC. | $3,053.16 | 01/08/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION | No dispute reported | 06/30/2026 | 1228832020 |
| Principal investigator 1 | Amgen Inc. | $12,678.08 | 01/02/2025 | Non-covered Recipient Entity MIDAMERICA CANCER CARE | A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1246644679 |